Freshpet, Inc. Reports Third Quarter 2026 Financial Results

Freshpet’s Q3 2026 net sales rose 10.0% to $317.8 million, while gross margin expanded to 44.5% from 39.5% and adjusted gross margin reached 50.0%, its highest in more than seven years. Adjusted EBITDA increased to $64.5 million from $54.6 million; reported net income fell to $29.7 million from $101.7 million, largely because the prior-year quarter included a $77.9 million deferred tax benefit. Freshpet raised and narrowed 2026 sales growth guidance to 12%–13% and adjusted EBITDA guidance to $215–$220 million, and expects positive free cash flow; it repurchased $102.3 million of shares during the first nine months.

Analysis

The quality of growth matters more than the headline margin expansion: sales gains are volume-led, while nine-month price/mix was a modest drag. That supports consumer adoption, but limits evidence of pricing power and leaves growth exposed to promotions or lower-cost substitutes. Gross-margin improvement also reflects lower inputs and plant leverage; neither should be treated as fully structural until sustained through changing input costs and higher logistics expense. The key operating tension is that adjusted SG&A grew faster than sales in Q3, absorbing part of the gross-margin gain. Watch logistics cost per unit and incremental SG&A against volume as the test of whether scale converts into durable earnings.

The raised sales outlook and lower expected capex improve the near-term cash-flow narrative, but do not by themselves establish a higher steady-state FCF run rate: capex timing and proceeds from the equity investment affect reported cash, while the buyback has already deployed substantial capital. With convertible debt still outstanding, capital allocation should be judged against returns on manufacturing capacity, not only per-share accretion. Over 1–3 months, the call’s commentary on volume, logistics and capex execution is the catalyst; over 6–18 months, the question is whether capacity supports growth without renewed cost pressure. The 2027 margin ambition is plausible but not yet demonstrated by nine-month profitability; do not extrapolate one quarter. Competition from established pet-food players and private-label substitution could constrain mix or force higher marketing spend.

Key Decisions for Investors

• Constructive, but avoid chasing the release without valuation and post-call price context. Consider a staged FRPT long on weakness only if management confirms volume momentum and that logistics costs are stabilizing; the thesis is falsified by a meaningful sales-outlook cut or sustained adjusted SG&A growth outpacing sales.
• Treat the gross-margin step-up as partly cyclical until proven otherwise. Track input-cost commentary and whether adjusted gross margin can remain consistent with the company’s 2027 floor of 49%; a miss would challenge the structural operating-leverage thesis.
• Do not annualize Q3 adjusted EBITDA margin or treat the capex reduction as recurring FCF yet. Verify the timing and productivity of planned investment, working-capital needs, and the cash impact of buybacks on the conference call; weaker conversion of EBITDA to FCF would argue against adding.
• No clean peer pair trade is established from the supplied data. Monitor established pet-food competitors for launches, pricing and promotional intensity that could slow Freshpet’s volume growth or force higher media and distribution spending.